Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy

11012 Background: We sought to determine the prognostic significance of pathologic complete response (pCR) in soft tissue sarcoma (STS) in patients (pts) receiving neoadjuvant chemoradiotherapy (RTOG 9514) or radiotherapy (RTOG 0630) with long-term outcomes. Methods: RTOG has completed two phase II trials (RTOG 9514 and RTOG 0630) for pts with localized STS. Pts with high-grade STS ≥8 cm of extremities or body wall were enrolled to 9514 from 1997-2000 and received 3 cycles neoadjuvant chemotherapy (CT), interdigitated with RT, and 3 cycles postop CT. Pts with STS of extremities were enrolled to 0630 from 2008-2010 and received preoperative RT without CT. One pathology expert (DL) assessed pts for pCR at time of surgery without knowledge of disease outcomes. Overall and disease-free survival (OS and DFS) were calculated from the date of surgery. Pts that did not have surgery or had an amputation were excluded. Hazard ratios (HR) and p-values were estimated by multivariate Cox model stratified by study, where possible (i.e., > 0 events in both groups); otherwise p-values were calculated by stratified log-rank test. Results: Of 135 who had surgery, 123 were evaluable for pCR: 14/51 (27.5%) on 9514 and 14/72 (19.4%) on 0630 had pCR. With median follow-up of > 5 years for surviving pts, OS is 100% for pts with pCR vs. 5-year 76.5% (95% confidence interval 62.3-90.8) and 56.4% (43.3-69.5) for pts with < pCR in 9514 and 0630, respectively. pCR is associated with improved OS (p = 0.01) and DFS [HR 4.91 (1.51-15.93); p = 0.008] relative to < pCR. Local failure rate was 0% in pts with pCR vs. 5-year 11.7% (3.6-25.1) and 9.1% (3.3-18.5) for pts with < pCR in 9514 and 0630, respectively. Leiomyosarcoma/liposarcoma/myxofibrosarcoma are associated with better OS [hazard ratio 2.24 (1.12 and 4.45)] while liposarcoma/myxofibrosarcoma are associated with better DFS [hazard ratio 2.42 (1.23-4.76)]. Conclusions: Results from this analysis have demonstrated that pCR is associated with improved survival outcomes in pts with STS treated with either neoadjuvant RT or CT-RT. pCR should be considered as a survival surrogate for future STS studies. Clinical trial information: RTOG 9514 and RTOG 0630.

Download Full-text

The prognostic significance of surgical treatment for excessive elderly patients with soft tissue sarcoma

International Journal of Clinical Oncology ◽

10.1007/s10147-018-1255-x ◽

2018 ◽

Vol 23 (4) ◽

pp. 775-782 ◽

Cited By ~ 2

Author(s):

Hiroyuki Tsuchie ◽

Makoto Emori ◽

Hiroyuki Nagasawa ◽

Naohisa Miyakoshi ◽

Yasutaka Murahashi ◽

...

Keyword(s):

Surgical Treatment ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Elderly Patients ◽

Prognostic Significance

Download Full-text

Prognostic Significance of Histological Subtype in Soft Tissue Sarcoma With Distant Metastasis

In Vivo ◽

10.21873/invivo.11994 ◽

2020 ◽

Vol 34 (4) ◽

pp. 1975-1980

Author(s):

HIROYUKI TSUCHIE ◽

MAKOTO EMORI ◽

NAOHISA MIYAKOSHI ◽

HIROYUKI NAGASAWA ◽

KYOJI OKADA ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Distant Metastasis ◽

Prognostic Significance ◽

Histological Subtype

Download Full-text

First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of stage II and III extremity soft tissue sarcoma (STS).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.10075 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 10075-10075

Author(s):

K. K. Curtis ◽

J. B. Ashman ◽

C. P. Beauchamp ◽

M. D. Callister ◽

M. W. Dopp ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Neoadjuvant Chemoradiotherapy ◽

Stage Ii ◽

First Report ◽

Extremity Soft Tissue Sarcoma

Download Full-text

Prognostic Significance of Activated AKT Expression in Soft-Tissue Sarcoma

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-05-1732 ◽

2006 ◽

Vol 12 (10) ◽

pp. 3070-3077 ◽

Cited By ~ 47

Author(s):

Yasuhiko Tomita ◽

Takaya Morooka ◽

Yoshihiko Hoshida ◽

Binglin Zhang ◽

Ying Qiu ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Prognostic Significance

Download Full-text

Immunological and prognostic significance of novel ferroptosis-related genes in soft tissue sarcoma

PLoS ONE ◽

10.1371/journal.pone.0262234 ◽

2022 ◽

Vol 17 (1) ◽

pp. e0262234

Author(s):

Jiazheng Zhao ◽

Yi Zhao ◽

Xiaowei Ma ◽

Helin Feng ◽

Rongmin Cui

Keyword(s):

Dendritic Cell ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Immune Cells ◽

Plasmacytoid Dendritic Cell ◽

Prognostic Significance ◽

Enrichment Analysis ◽

Prognostic Models ◽

Immune Checkpoints ◽

Hub Genes

Background Ferroptosis has exhibited great potential in the treatment of cancer and has gained widespread attention in soft tissue sarcoma (STS). The aim was to explore the immunological and prognostic significance of novel ferroptosis-related genes in STS. Methods We identified ferroptosis-related differentially expressed genes (DEGs) in STS to construct the networks of enrichment analysis and protein-protein interaction. Subsequently, hub genes with prognostic significance were localized and a series of prognostic and immune analyses were performed. Results 40 ferroptosis-related DEGs were identified, of which HELLS, STMN1 EPAS1, CXCL2, NQO1, and IL6 were classified as hub genes and were associated with the prognosis in STS patients. In the results of the immune analysis, PDCD1, CTLA4, TIGIT, IDO1 and CD27 exhibited consistent intense correlations as immune checkpoint genes, as well as macrophage, neutrophil, cytotoxic cell, dendritic cell, interdigitating dendritic cell and plasmacytoid dendritic cell as immune cells. EPAS1 and HELLS might be independent prognostic factors for STS patients, and separate prognostic models were constructed by using them. Conclusions We recognized novel ferroptosis-related genes with prognostic value in STS. Furthermore, we searched out potential immune checkpoints and critical immune cells.

Download Full-text